Ocular Therapeutix, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ocular Therapeutix, Inc.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.
Manufacturers can apply for permanent Medicare reimbursement codes on a quarterly basis rather than annually going forward to allow for more frequent coding awards. Recently about two dozen drugs, including three biosimilars, received permanent codes earlier than usual.
- Controlled Release
- Drug Delivery
- Implantable Devices
Surgical Equipment & Devices
- Surgical Sealants
- Large Molecule